Skip to main content
Premium Trial:

Request an Annual Quote

Waters Posts Double-Digit Boost in Q3 Sales, Profit

This article has been updated from a previous version to include additional information from a conference call.
 
NEW YORK (GenomeWeb News) – Waters said today that its sales increased nearly 10 percent and its net profit swelled almost 35 percent in the third quarter, while it trimmed its R&D costs around 10 percent.
 
Waters brought in revenues of $386.3 million for the three-month period ended Sept. 27, versus $352.6 million in the third quarter of 2007. Foreign currency translation accounted for around 5 percent of the sales boost, the company said in its earnings statement.
 
Waters CFO John Ornell said in a conference call this morning that sales in the US rose only one percent on weakening demand from large pharmaceutical companies and a "strong" prior-year comparison. Sales in Europe, meanwhile, rose seven percent, Sales in Japan were up 10 percent, and sales in Asia outside of Japan increased 11 percent.

Ornell said that within the Waters division, instrument systems grew by three percent, while recurring revenues grew nine percent driven by double-digit service growth. the company's TA Instruments division saw sales growth of 14 percent over the prior-year quarter, he said.

 
The Milford, Mass.-based manufacturer of chromatography, mass spectrometry, and thermal analysis systems posted a profit of $71.5 million, or $.71 per share, for the third quarter, compared to net earnings of $53.3 million, or $.52 per share, for the third quarter of 2007.
 
Waters’ R&D costs dipped 9 percent to $19.9 million from $22 million, while its SG&A expenses ticked up almost two percent to $107.5 million from $105.6 million.
 
Company CEO Douglas Berthiaume said in a statement that the strong quarter is an affirmation of the company’s strategy in “these tough economic times.”
 
The firm finished the quarter with $893 million in cash, cash equivalents, and short-term investments.
 
Ornell acknowledged the uncertainty in the financial markets, noting that it is likely to lead to slow customer spending, but he added that the company's internal analysis "suggests that businesses will continue to spend on the technologies and solutions we provide and allow us to grow around percent organically in the fourth quarter."
 
Currency fluctuations should reduce that growth by about 2 percent, bringing overall fourth-quarter growth to around 4 percent, he said.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.